Evaluation of Serum Apolipoprotein E as a Potential Biomarker for Pharmacological Therapeutic Efficacy Monitoring in Dopamine Dictated Disease Spectrum of Schizophrenia and Parkinson’s disease: A Preliminary Study
| Autor: | Gururao Hariprasad, Domada Ratna Kumar, Komal Rani, Surabhi Swarnkar, Ashish Gupta, Vinay Goyal, Rishab Gupta, Mohd Imran Khan, Perumal Vanamail, Ruchika Pokhriyal, Gaurav Kumar, Manjari Tripathi, Rakesh K Chadda |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
Apolipoprotein E Parkinson's disease Disease Bioinformatics lcsh:RC346-429 therapeutic biomarker 03 medical and health sciences 0302 clinical medicine drug side effects Dopamine medicine lcsh:Neurology. Diseases of the nervous system Original Research apolipoprotein E business.industry Disease spectrum Dopaminergic General Medicine medicine.disease schizophrenia 030104 developmental biology Schizophrenia Potential biomarkers Parkinson’s disease dopamine business 030217 neurology & neurosurgery medicine.drug |
| Zdroj: | Journal of Central Nervous System Disease Journal of Central Nervous System Disease, Vol 10 (2018) |
| ISSN: | 1179-5735 |
| Popis: | Aim of the Study:Parkinson’s disease and schizophrenia are disease end points of dopaminergic deficit and hyperactivity, respectively, in the mid brain. Accordingly, current medications aim to restore normal dopamine levels, overshooting of which results in adverse effects of psychosis and extra-pyramidal symptoms, respectively. There are currently no available laboratory tests to guide treatment decisions or help predict adverse side effects of the drugs. The aim was to therefore explore the possibility of using apolipoprotein E as a biomarker to monitor pharmacological intervention in dopamine dictated states of Parkinson’s disease and schizophrenia for optimum therapy.Methods:Naïve and treated, Parkinson’s disease and schizophrenic patients were recruited from neurology and psychiatry clinics. Serum of healthy volunteers was collected as controls. Serum concentrations of apolipoprotein E was estimated by enzyme-linked immunosorbent assay (ELISA). Pathway analysis was carried out to delineate the interactions of apolipoprotein E in Parkinson’s disease and schizophrenia.Results:Apolipoprotein E levels are higher in Parkinson’s disease patients as compared with schizophrenic samples ( P Conclusion:Apolipoprotein E concentration across the dopaminergic spectrum suggests that it can be pursued not only as a potential biomarker in schizophrenia and Parkinson’s disease, but can also be an effective tool for clinicians to determine efficacy of drug-based therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|